The network of P-glycoprotein and microRNAs interactions

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 253-263

  Lopes Rodrigues, Vanessa ^a   Seca, Hugo ^a   Sousa, Diana ^a   Sousa, Emília ^a   Lima, Raquel T ^a   Vasconcelos, M Helena ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

cancer; drug resistance; exosomes; microRNAs; microvesicles; P glycoprotein

Indexed keywords

MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

BINDING AFFINITY; BINDING SITE; CANCER RESISTANCE; CELLULAR DISTRIBUTION; DOWN REGULATION; EXOSOME; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HUMAN; MICROVASCULATURE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; RNA TRANSCRIPTION; RNA TRANSPORT; SIGNAL TRANSDUCTION;

CANCER; DRUG RESISTANCE; EXOSOMES; MICRORNAS; MICROVESICLES; P-GLYCOPROTEIN;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; P-GLYCOPROTEIN; SIGNAL TRANSDUCTION;

EID: 84900001904     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28500     Document Type: Review

References (183)

1. Sharom FJ,. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27.
2. Eckford PD, Sharom FJ,. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009; 109: 2989-3011.
3. Sonneveld P,. Multidrug resistance in haematological malignancies. J Int Med 2000; 247: 521-34.
4. Leith C,. Multidrug resistance in leukemia. Curr Opin Hematol 1998; 5: 287-91.
5. Musto P, Melillo L, Lombardi G, et al. High risk of early resistant relapse or leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50-3.
6. Marie JP, Zittoun R, Sikic BI,. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-92.
7. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-12.
8. Zhou DC, Marie JP, Suberville AM, et al. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-85.
9. Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-8.
10. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990; 76: 2065-71.
11. Wuchter C, Leonid K, Ruppert V, et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711-21.
12. Kanerva J, Tiirikainen MI, Makipernaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol 2001; 18: 27-36.
13. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092-8.
14. Olson DP, Taylor BJ, La M, et al. The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymph 2005; 46: 681-91.
15. Casale F, D'Angelo V, Addeo R, et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12: 1201-7.
16. De Moerloose B, Swerts K, Benoit Y, et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003; 20: 381-91.
17. Plasschaert SL, Vellenga E, de Bont ES, et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymph 2003; 44: 85-95.
18. Shaffer BC, Gillet JP, Patel C, et al. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 2012; 15: 62-9.
19. Thorgeirsson SS, Huber BE, Sorrell S, et al. Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 1987; 236: 1120-2.
20. Kohno K, Sato S, Takano H, et al. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 1989; 165: 1415-21.
21. Maillefert JF, Maynadie M, Tebib JG, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996; 35: 430-5.
22. Ho GT, Moodie FM, Satsangi J,. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003; 52: 759-66.
23. Sui H, Zhou S, Wang Y, et al. COX-2 contributes to P-glycoprotein- mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis 2011; 32: 667-75.
24. Bush JA, Li G,. Regulation of the Mdr1 isoforms in a p53-deficient mouse model. Carcinogenesis 2002; 23: 1603-7.
25. Sampath J, Sun D, Kidd VJ, et al. Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 2001; 276: 39359-67.
26. Yamada T, Takaoka AS, Naishiro Y, et al. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000; 60: 4761-6.
27. Baird RD, Kaye SB,. Drug resistance reversal-are we getting closer? Eur J Cancer 2003; 39: 2450-61.
28. Naito S, Sakamoto N, Kotoh S, et al. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993; 24: 156-60.
29. Kakehi Y, Kanamaru H, Yoshida O, et al. Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 1988; 139: 862-5.
30. Kim WJ, Kakehi Y, Kinoshita H, et al. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 1996; 156: 506-11.
31. Wu L, Smythe AM, Stinson SF, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res 1992; 52: 3029-34.
32. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995; 95: 2205-14.
33. Reinecke P, Schmitz M, Schneider EM, et al. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types. Cancer Invest 2000; 18: 614-25.
34. Kanamaru H, Kakehi Y, Yoshida O, et al. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989; 81: 844-9.
35. Chaudhary PM, Roninson IB,. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
36. Smyth MJ, Krasovskis E, Sutton VR, et al. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 1998; 95: 7024-9.
37. Ruefli AA, Tainton KM, Darcy PK, et al. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 2002; 9: 1266-72.
38. Liu YY, Gupta V, Patwardhan GA, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 2010; 9: 145.
39. Johnstone RW, Ruefli AA, Smyth MJ,. Multiple physiological functions for multidrug transporter P-glycoprotein? Trend Biochem Sci 2000; 25: 1-6.
40. Seca H, Lima RT, Guimaraes JE, et al. Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib. Hematology 2011; 16: 100-8.
41. Lima RT, Guimaraes JE, Vasconcelos, MH,. Overcoming K562Dox resistance to STI571 (Gleevec) by downregulation of P-gp expression using siRNAs. Cancer Ther 2007; 5: 67-76.
42. Xia Z, Zhang L, Chen Q, et al. Stable reversal of multidrug resistance in colon cancer cells by RNA interference targeting the MDR1 gene. Mol Med Rep 2009; 2: 579-84.
43. Xu H, Hong FZ, Li S, et al. Short hairpin RNA-mediated MDR1 gene silencing increases apoptosis of human ovarian cancer cell line A2780/Taxol. Chin J Cancer Res 2012; 24: 138-42.
44. Sharom FJ,. The P-glycoprotein multidrug transporter. Essays Biochem 2011; 50: 161-78.
45. Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 2012; 19: 1946-2025.
46. Palmeira A, Vasconcelos MH, Paiva A, et al. Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 2012; 83: 57-68.
47. Palmeira A, Sousa E, Vasconcelos MH, et al. Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Design 2012; 18: 4197-214.
48. Eichhorn T, Efferth T,. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 2012; 141: 557-70.
49. Gottesman MM, Pastan I,. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
50. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
51. Gros P, Croop J, Housman D,. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986; 47: 371-80.
52. Schinkel AH, Kemp S, Dolle M, et al. N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993; 268: 7474-81.
53. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-22.
54. Jin MS, Oldham ML, Zhang Q, et al. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012; 490: 566-9.
55. Omote H, Al-Shawi MK,. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J 2006; 90: 4046-59.
56. Willingham MC, Richert ND, Cornwell MM, et al. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987; 35: 1451-6.
57. Fu D, Arias IM,. Intracellular trafficking of P-glycoprotein. Int J Biochem Cell Biol 2012; 44: 461-4.
58. Calcabrini A, Meschini S, Stringaro A, et al. Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells. Histochem J 2000; 32: 599-606.
59. Molinari A, Calcabrini A, Meschini S, et al. Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 2002; 3: 653-70.
60. Baldini N, Scotlandi K, Serra M, et al. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 1995; 68: 226-39.
61. Fu D, Bebawy M, Kable EP, et al. Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: implications in multidrug resistance in cancer. Int J Cancer 2004; 109: 174-81.
62. Molinari A, Calcabrini A, Meschini S, et al. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 1998; 75: 885-93.
63. Molinari A, Cianfriglia M, Meschini S, et al. P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer 1994; 59: 789-95.
64. Fu D, Roufogalis BD,. Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation. American journal of physiology. Cell Physiol 2007; 292: C1543-52.
65. Rajagopal A, Simon SM,. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 2003; 14: 3389-99.
66. Solazzo M, Fantappie O, Lasagna N, et al. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res 2006; 312: 4070-8.
67. Munteanu E, Verdier M, Grandjean-Forestier F, et al. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Biochem Pharmacol 2006; 71: 1162-74.
68. Paterson JK, Gottesman MM,. P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res 2007; 313: 3100-5.
69. Ferrao P, Sincock P, Cole S, et al. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia. Leuk Res 2001; 25: 395-405.
70. Meschini S, Calcabrini A, Monti E, et al. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. Int J Cancer 2000; 87: 615-28.
71. Sun J, Yeung CA, Co NN, et al. Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-kappaB in R-HepG2 cell line. PloS One 2012; 7: e40720.
72. Shtil AA, Azare J,. Redundancy of biological regulation as the basis of emergence of multidrug resistance. Int Rev Cytol 2005; 246: 1-29.
73. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-8.
74. Correa S, Binato R, Du Rocher B, et al. Wnt/beta-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer 2012; 12: 303.
75. Sukhai M, Piquette-Miller M,. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci 2000; 3: 268-80.
76. Shen H, Xu W, Luo W, et al. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 2011; 39: 558-69.
77. Thottassery JV, Zambetti GP, Arimori K, et al. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 1997; 94: 11037-42.
78. Vilaboa NE, Galan A, Troyano A, et al. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J Biol Chem 2000; 275: 24970-6.
79. Hu Z, Jin S, Scotto KW,. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem 2000; 275: 2979-85.
80. Ziemann C, Burkle A, Kahl GF, et al. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis 1999; 20: 407-14.
81. Yeh SY, Pan HJ, Lin CC, et al. Hyperglycemia induced down-regulation of renal P-glycoprotein expression. Eur J Pharmacol 2012; 690: 42-50.
82. Schondorf T, Kurbacher CM, Gohring UJ, et al. Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 2002; 22: 2199-203.
83. Baker EK, Johnstone RW, Zalcberg JR, et al. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 2005; 24: 8061-75.
84. Riordan JR, Deuchars K, Kartner N, et al. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817-9.
85. Gomez-Martinez A, Garcia-Morales P, Carrato A, et al. Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 2007; 5: 641-53.
86. Kusaba H, Nakayama M, Harada T, et al. Association of 5′ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 1999; 262: 924-32.
87. Scotto KW, Egan DA,. Transcriptional regulation of MDR genes. Cytotechnology 1998; 27: 257-69.
88. Jin S, Scotto KW,. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol 1998; 18: 4377-84.
89. Lee CH, Bradley G, Ling V,. Overexpression of the class II P-glycoprotein gene in primary rat hepatocyte culture: evidence for increased mRNA stability. Cell Growth Differ 1995; 6: 347-54.
90. Yague E, Armesilla AL, Harrison G, et al. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003; 278: 10344-52.
91. Orom UA, Nielsen FC, Lund AH., MicroRN A-, 10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-71.
92. Filipowicz W, Bhattacharyya SN, Sonenberg N,. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
93. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R,. Control of translation and mRNA degradation by miRNAs and siRNAs. Gene Dev 2006; 20: 515-24.
94. Liu J,. Control of protein synthesis and mRNA degradation by microRNAs. Curr Opin Cell Biol 2008; 20: 214-21.
95. Brodersen P, Voinnet O,. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 2009; 10: 141-8.
96. John B, Enright AJ, Aravin A, et al. Human MicroRNA targets. PLoS Biol 2004; 2: e363.
97. Berezikov E,. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet 2011; 12: 846-60.
98. He L, Hannon GJ,. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-31.
99. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-34.
100. Place RF, Li LC, Pookot D, et al. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 2008; 105: 1608-13.
101. Dong J, Zhao YP, Zhou L, et al. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 2011; 42: 8-14.
102. Vasudevan S, Tong Y, Steitz JA,. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-4.
103. Rigoutsos I,. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. Cancer Res 2009; 69: 3245-8.
104. Piriyapongsa J, Bootchai C, Ngamphiw C, et al. microPIR: an integrated database of microRNA target sites within human promoter sequences. PloS One 2012; 7: e33888.
105. Zhao X, Yang L, Hu J, et al. miR-138 might reverse multidrug resistance of leukemia cells. Leuk Res 2010; 34: 1078-82.
106. Zhang H, Li M, Han Y, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55: 2545-51.
107. Fu LL, Wen X, Bao JK, et al. MicroRNA-modulated autophagic signaling networks in cancer. Int J Biochem Cell Biol 2012; 44: 733-6.
108. Lima RT, Busacca S, Almeida GM, et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011; 47: 163-74.
109. Bueno MJ, Malumbres M,. MicroRNAs and the cell cycle. Biochim Biophys Acta 2011; 1812: 592-601.
110. Bueno MJ, Perez de Castro I, Malumbres M,. Control of cell proliferation pathways by microRNAs. Cell Cycle 2008; 7: 3143-8.
111. Li MA, He L,. microRNAs as novel regulators of stem cell pluripotency and somatic cell reprogramming. BioEssays 2012; 34: 670-80.
112. Bethune J, Artus-Revel CG, Filipowicz W,. Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells. EMBO Rep 2012; 13: 716-23.
113. Huntzinger E, Izaurralde E,. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 2011; 12: 99-110.
114. Slezak-Prochazka I, Durmus S, Kroesen BJ, et al. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA 2010; 16: 1087-95.
115. Davis-Dusenbery BN, Hata A,. Mechanisms of control of microRNA biogenesis. J Biochem 2010; 148: 381-92.
116. Melo SA, Moutinho C, Ropero S, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010; 18: 303-15.
117. Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev 2008; 22: 3172-83.
118. Wang J, Lu M, Qiu C, et al. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res 2010; 38: D119-22.
119. Amiel J, de Pontual L, Henrion-Caude A,. miRNA, development and disease. Adv Genet 2012; 80: 1-36.
120. Hinton A, Hunter S, Reyes G, et al. From pluripotency to islets: miRNAs as critical regulators of human cellular differentiation. Adv Genet 2012; 79: 1-34.
121. Natarajan R, Putta S, Kato M,. MicroRNAs and diabetic complications. J Cardiovasc Transl Res 2012; 5: 413-22.
122. van Rooij E, Olson EN,. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012; 11: 860-72.
123. Liu H,. MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci 2012; 69: 3587-99.
124. Singh PK, Brand RE, Mehla K,. MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol 2012; 9: 334-44.
125. Schetter AJ, Okayama H, Harris CC,. The role of microRNAs in colorectal cancer. Cancer J 2012; 18: 244-52.
126. Seca H, Almeida GM, Guimaraes JE, et al. miR signatures and the role of miRs in acute myeloid leukaemia. Eur J Cancer 2010; 46: 1520-7.
127. Borralho PM, Simoes AE, Gomes SE, et al. miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PloS One 2011; 6: e23787.
128. Toscano-Garibay JD, Aquino-Jarquin G,. Regulation exerted by miRNAs in the promoter and UTR sequences: MDR1/P-gp expression as a particular case. DNA Cell Biol 2012; 31: 1358-64.
129. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-9.
130. Feng DD, Zhang H, Zhang P, et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011; 15: 2164-75.
131. Bao L, Hazari S, Mehra S, et al. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 2012; 180: 2490-503.
132. Ikemura K, Yamamoto M, Miyazaki S, et al. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol 2013; 83: 399-405.
133. Pan X, Wang ZX, Wang R., MicroRN A-, 21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010; 10: 1224-32.
134. Schramedei K, Morbt N, Pfeifer G, et al. MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 2011; 30: 2975-85.
135. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
136. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-84.
137. Seca H LR, Lopes-Rodrigues V, Guimarães JE, et al. Targeting miR-21 induces autophagy and chemosensitivity of leukemia cells. Curr Drug Targets 2013; 14: 1135-43.
138. Gong C, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127-37.
139. Valeri N, Gasparini P, Braconi C, et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A 2010; 107: 21098-103.
140. Shi L, Chen J, Yang J, et al. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010; 1352: 255-64.
141. Bourguignon LY, Spevak CC, Wong G, et al. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009; 284: 26533-46.
142. Yang L, Li N, Wang H, et al. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep 2012; 28: 592-600.
143. Boyerinas B, Park SM, Murmann AE, et al. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 2012; 130: 1787-97.
144. Zhao X, Yang L, Hu J,. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011; 30: 55.
145. Chen J, Tian W, Cai H, et al. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med Oncol 2012; 29: 2527-34.
146. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-8.
147. Xu Y, Xia F, Ma L, et al. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett 2011; 310: 160-9.
148. Jaiswal R, Luk F, Gong J, et al. Microparticle conferred microRNA profiles-implications in the transfer and dominance of cancer traits. Mol Cancer 2012; 11: 37.
149. Tsang TY, Tang WY, Chan JY, et al. P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis 2011; 16: 524-35.
150. Lee TH, D'Asti E, Magnus N, et al. Microvesicles as mediators of intercellular communication in cancer-the emerging science of cellular 'debris'. Semin Immunopathol 2011; 33: 455-67.
151. Levchenko A, Mehta BM, Niu X, et al. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A 2005; 102: 1933-8.
152. Lee Y, El Andaloussi S, Wood MJ,. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 21: R125-34.
153. Bebawy M, Combes V, Lee E, et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009; 23: 1643-9.
154. Gong J, Jaiswal R, Mathys JM, et al. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 2012; 38: 226-34.
155. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
156. Yang M, Chen J, Su F, et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011; 10: 117.
157. Umezu T, Ohyashiki K, Kuroda M, et al. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013; 32: 2747-55.
158. Ogawa R, Tanaka C, Sato M, et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem Biophys Res Commun 2010; 398: 723-9.
159. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-44.
160. Jaiswal R, Gong J, Sambasivam S, et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 2012; 26: 420-9.
161. Pasquier J, Galas L, Boulange-Lecomte C, et al. Different modalities of intercellular membrane exchanges mediate cell-to-cell p-glycoprotein transfers in MCF-7 breast cancer cells. J Biol Chem 2012; 287: 7374-87.
162. Jaiswal R, Luk F, Dalla PV, et al. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PloS One 2013; 8: e61515.
163. Elhassan MO, Christie J, Duxbury MS,. Homo sapiens systemic RNA interference-defective-1 transmembrane family member 1 (SIDT1) protein mediates contact-dependent small RNA transfer and microRNA-21-driven chemoresistance. J Biol Chem 2012; 287: 5267-77.
164. Anuchapreeda S, Leechanachai P, Smith MM, et al. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002; 64: 573-82.
165. Chearwae W, Anuchapreeda S, Nandigama K, et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 2004; 68: 2043-52.
166. O'Connor R, Ooi MG, Meiller J, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013; 71: 1357-68.
167. Tucci M, Quatraro C, Dammacco F, Silvestris F,. Role of active drug transporters in refractory multiple myeloma. Curr Top Med Chem 2009; 9: 218-24.
168. Dalton WS,. Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 1997; 34: 3-8.
169. Pilarski LM, Mant MJ, Belch AR,. Drug resistance in multiple myeloma: novel therapeutic targets within the malignant clone. Leuk Lymph 1999; 32: 199-210.
170. Yan F, Wang XM, Liu ZC, et al. JNK1, JNK2, and JNK3 are involved in P-glycoprotein-mediated multidrug resistance of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int 2010; 9: 287-95.
171. Sun Z, Zhao Z, Li G, et al. Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010; 96: 90-6.
172. Zhou Y, Ling XL, Li SW, et al. Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol 2010; 16: 2291-7.
173. Stewart DJ,. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234.
174. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
175. Stewart DJ, Tomiak E, Shamji FM, et al. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 2004; 44: 241-9.
176. Richert ND, Aldwin L, Nitecki D, et al. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 1988; 27: 7607-13.
177. Stordal B, Hamon M, McEneaney V, et al. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One 2012; 7: e40717.
178. Xu L, Cai J, Yang Q, et al. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies. J Cancer Res Clin Oncol 2013; 139: 1257-77.
179. Trock BJ, Leonessa F, Clarke R,. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
180. Gottesman MM, Fojo T, Bates SE,. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
181. de Vries NA, Buckle T, Zhao J, et al. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 2012; 30: 443-9.
182. Wartenberg M, Richter M, Datchev A, et al. Glycolytic pyruvate regulates P-Glycoprotein expression in multicellular tumor spheroids via modulation of the intracellular redox state. J Cell Biochem 2010; 109: 434-46.
183. Haar CP, Hebbar P, Wallace GCt, et al. Drug resistance in glioblastoma: a mini review. Neurochem Res 2012; 37: 1192-200.